Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2017

Woo C G, Seo S, Kim S W, Jang S J, Park K S, Song J Y, Lee B, Richards M W, Bayliss R, Lee D H, Choi J

Abstract excerpt

Background: Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the standard of care in advanced ALK-rearranged non-small cell lung cancer (NSCLC), but the treatment outcomes and duration of response vary widely. Echinoderm microtubule-associated protein-like 4 (EML4)-ALK is the most common translocation, and the fusion variants show different sensitivity to crizotinib in vitro. However, there...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbazoles
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiplex Polymerase Chain Reaction

Share to Oncogene Proteins, Fusion

Share to Piperidines

Share to Pyrazoles

Share to Pyridines

Share to Sulfones

Source

Identifiers

PMID: 28039177
DOI: 10.1093/annonc/mdw693

Genes

ALK
EML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.PMID 28039177Read ↗

Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.Semantic proximity Read ↗

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung CancerSemantic proximity Read ↗

Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.Semantic proximity Read ↗

Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLCSemantic proximity Read ↗

Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study.Semantic proximity Read ↗

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Semantic proximity Read ↗

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.Semantic proximity Read ↗

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.